Privium Fund Management B.V. Purchases 3,000 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Privium Fund Management B.V. raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 11.0% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 30,347 shares of the company’s stock after acquiring an additional 3,000 shares during the period. Privium Fund Management B.V.’s holdings in CRISPR Therapeutics were worth $1,426,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of CRSP. Capital International Investors boosted its holdings in CRISPR Therapeutics by 27.8% during the first quarter. Capital International Investors now owns 7,837,074 shares of the company’s stock worth $534,175,000 after purchasing an additional 1,702,624 shares during the last quarter. SR One Capital Management LP acquired a new position in shares of CRISPR Therapeutics during the 1st quarter worth about $71,496,000. Farallon Capital Management LLC acquired a new position in shares of CRISPR Therapeutics during the 2nd quarter worth about $28,625,000. Avoro Capital Advisors LLC acquired a new stake in shares of CRISPR Therapeutics in the first quarter valued at about $28,599,000. Finally, Marshall Wace LLP acquired a new stake in shares of CRISPR Therapeutics in the second quarter valued at about $10,078,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insider Activity

In related news, CEO Samarth Kulkarni sold 4,293 shares of the firm’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the transaction, the chief executive officer now owns 226,540 shares in the company, valued at approximately $10,484,271.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 4,293 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the transaction, the chief executive officer now directly owns 226,540 shares in the company, valued at $10,484,271.20. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the transaction, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Stock Performance

CRSP stock opened at $51.62 on Friday. CRISPR Therapeutics AG has a 52 week low of $43.42 and a 52 week high of $91.10. The company has a market capitalization of $4.41 billion, a PE ratio of -18.24 and a beta of 1.67. The company’s 50-day simple moving average is $47.45 and its 200 day simple moving average is $52.18.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.41. The company had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period last year, the firm earned ($1.41) earnings per share. On average, analysts forecast that CRISPR Therapeutics AG will post -5.47 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on CRSP shares. Royal Bank of Canada restated a “sector perform” rating and issued a $53.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday. Truist Financial lowered their target price on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. Rodman & Renshaw started coverage on shares of CRISPR Therapeutics in a report on Friday, August 2nd. They issued a “buy” rating and a $90.00 target price on the stock. Finally, Barclays lowered their price target on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Wednesday. Three analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $74.94.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.